CB699 / Crescendo Biologics - LARVOL DELTA

CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumors (AACR 2024) - "CB699 is a novel MSLN-binding CD137 and CD40 dual agonist that selectively enhances immune cell activity by enhancing both T cell and APC signaling axes. CB699 is positioned to enter clinical development."

Immune cell • IO biomarker • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CD34 • CD40 • CD86 • MSLN • TNFRSF9

Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 (GlobeNewswire) - "The results demonstrated CB699’s ability to conditionally enhance both T cell and antigen-presenting cell (APC) signalling axes, providing a comprehensive anti-cancer immune response; and The trispecific format was able to drive conditional CD40 agonism in the presence of either CD137+ or MSLN+ cells, and similarly, conditional CD137 agonism in the presence of either CD40+ or MSLN+ cells, potentially providing a potent yet safe way to target heterogeneous tumours."

Preclinical • Oncology • Solid Tumor